IMMU Immunicum AB

Invitation to presentation of Mendus’ year-end report for 2023

Invitation to presentation of Mendus’ year-end report for 2023

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session.



Listen to the presentation webcast:

Please send any questions ahead of the presentation to



For more information, please contact:

Erik Manting, CEO

E-mail:



About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Attachment



EN
09/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Sean Conroy
  • Sean Conroy

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

Sean Conroy
  • Sean Conroy

Mendus - Regulatory green light for CADENCE trial

The Human Research Ethics Committee (HREC) has provided the green light to commence enrolment for Mendus’s AMLM22-CADENCE trial from April 2024. This Phase II trial in collaboration with the Australasian Leukaemia and Lymphoma Group, a clinical trial research group focused on haematological cancers, will evaluate lead cancer vaccine vididencel, in combination with standard of care oral azacitidine (Onureg) as a maintenance treatment for acute myeloid leukaemia (AML). A pivotal global registratio...

 PRESS RELEASE

Mendus to present NK cell program progress at the Innate Killer Summit

Mendus to present NK cell program progress at the Innate Killer Summit Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Killer Summit is a lead...

 PRESS RELEASE

Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Su...

Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Summit Pressmeddelande Stockholm den 19 mars 2024 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag att bolaget kommer att presentera utvecklingen av sitt NK-cellsprogram vid den årliga Innate Killer Cell Summit, en ledande konferens för NK-cellsbaserade terapier. Mendus forskningschef Satwinder Kaur Singh, PhD, kommer att vara experttalare på 9th Annual Innate Killer Summit som hålls den 18-20 mars i San Diego, CA, USA. Innate Killer Summit är e...

 PRESS RELEASE

Mendus’ major shareholders and members of the Board of Directors and M...

Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscript...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch